Oxaliplatin and fluorouracil: bolus coadministration regimens
Zaniboni, A.; Meriggi, F.
Tumori 87(6): A24-A25
2001
ISSN/ISBN: 0300-8916 PMID: 11995700 Document Number: 531623
Document emailed within 1 workday
Related Documents
Fujii, S.; Kitano, S.; Ikenaka, K.; Fukushima, M.; Nakamura, H.; Maehara, Y.; Shirasaka, T. 1980: Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil Gan 71(1): 100-106Shaib, W.; Lee, V.; Saif, M.W. 2009: Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity In Vivo 23(5): 821-826
Kalofonos, H.P.; Papakostas, P.; Makatsoris, T.; Papamichael, D.; Vourli, G.; Xanthakis, I.; Aravantinos, G.; Papadimitriou, C.; Pentheroudakis, G.; Varthalitis, I.; Samelis, G.; Syrigos, K.N.; Xiros, N.; Stavropoulos, M.; Kosmidis, P.; Christodoulou, C.; Linardou, H.; Skondra, M.; Pectasides, D.; Economopoulos, T.; Fountzilas, G. 2010: Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer Anticancer Research 30(10): 4325-4333
Ohtani, H.; Arimoto, Y.; Nishio, K.; Kanamiya, Y.; Oba, H.; Adachi, K.; Shintani, M.; Nakamura, R.; Yui, S. 2008: Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(10): 1769-1774
Zampino, M.G.; Lorizzo, K.; Rocca, A.; Locatelli, M.; Zorzino, L.; Manzoni, S.; Mazzetta, C.; Fazio, N.; Biffi, R.; De Braud, F. 2006: Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer Anticancer Research 26(3b): 2425-2428
Lu, J.-w.; Zhou, Z.-f.; Yin, B.-j.; Liu, D.-l.; Feng, J.-f.; Zhu, L.-j.; Pan, L.-x. 2005: Chronomodulated chemotherapy of oxaliplatin, 5-fluorouracil and folinic acid for advanced gastric cancer Zhonghua Zhong Liu Za Zhi 27(11): 695-697
Chauffert, B.; Bonnotte, B.; Chvetzoff, G.; Flesch, M. 1998: The major response of metastatic kidney cancer to the combination of oxaliplatin, 5-fluorouracil and folinic acid (FOX-FOL) Presse Medicale 27(18): 859
Shitara, K.; Munakata, M.; Muto, O.; Kasai, M.; Okada, R.; Mitobe, S.; Sakata, Y. 2007: Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(7): 1079-1084
Laudani, A.; Gebbia, V.; Leonardi, V.; Savio, G.; Borsellino, N.; Cusimano, M.Pia.; Calabria, C.; Stefano, R.; Agostara, B. 2004: Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma Anticancer Research 24(2c): 1139-1142
Failli, A.; Legitimo, A.; Orsini, G.; Castagna, M.; Spisni, R.; Miccoli, P.; Consolini, R. 2013: Antiproliferative effects of 5-fluorouracil and oxaliplatin in colon cancer cell lines: comparison of three different cytotoxicity assays Journal of Biological Regulators and Homeostatic Agents 27(1): 275-284
Takahashi, H.; Ishikawa, T.; Iwata, N.; Baba, H.; Masuda, T.; Okazaki, S.; Matsuyama, T.; Ishiguro, M.; Kobayashi, H.; Iida, S.; Uetake, H.; Sugihara, K. 2013: A case of advanced rectal cancer treated with leucovorin, fluorouracil, and oxaliplatin plus panitumumab preoperative chemotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(12): 1953-1955
Wang, Z.-H.; Guo, J.; Chen, Z.; Li, C.-Z.; Sheng, L.-J.; Zhou, D.-G.; Liu, B.; Liu, J.; Wang, Q.-C.; Zhang, E.-N. 2008: Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer Zhonghua Zhong Liu Za Zhi 30(5): 389-391
Zhao, L.; Li, X.-y.; Bai, C.-m.; Chen, S.-c. 2008: Post-operative adjuvant treatment with oxaliplatin, fluorouracil, and leucovorin for local advanced gastric cancer Zhonghua Yi Xue Za Zhi 88(18): 1264-1266
Johnson, S.; Peter, J.V.; Thomas, K.; Jeyaseelan, L.; Cherian, A.M. 1996: Evaluation of two treatment regimens of pralidoxime (1 gm single bolus dose vs 12 gm infusion) in the management of organophosphorus poisoning Journal of the Association of Physicians of India 44(8): 529-531
Neyns, B.; Van Nieuwenhove, Y.; Aerts, M.; Fontaine, C.; Vermeij, J.; Schallier, D.; Decoster, L.; De Mey, J.; Vandenbroucke, F.; Hoorens, A.; Delvaux, G.; De Gréve, J. 2006: Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases Anticancer Research 26(1b): 611-619
Liang, X-Bo.; Hou, S-Huai.; Li, Y-Ping.; Wang, L-Chun.; Zhang, X.; Yang, J. 2010: Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis Chinese Medical Journal 123(22): 3314-3318
Mishima, H.; Ikenaga, M.; Ishida, H.; Iwamoto, S.; Morimoto, T.; Narahara, H.; Kato, T.; Tsujie, M.; Kitai, T.; Fukunaga, M.; Nakanishi, M.; Tsujinaka, T.; Furukawa, H.; Taguchi, T. 2007: Multicenter phase II study of irinotecan plus bolus fluorouracil/l-leucovorin for metastasic colorectal cancer Anticancer Research 27(2): 1003-1008
Nakayasu, Y.; Yoshimatsu, K.; Yokomizo, H.; Osawa, G.; Yano, Y.; Nakayama, M.; Sakuma, A.; Yamaguchi, K.; Shiozawa, S.; Shimakawa, T.; Katsube, T.; Naritaka, Y. 2013: Two cases of locally advanced colorectal cancer curatively resected after neoadjuvant chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin plus panitumumab Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(12): 2029-2031
Najam, R.; Bano, N.; Mirza, T.; Hassan, S. 2014: Adverse effects on cardiovascular status and lipid levels of albino Wistar rats treated with cisplatin and oxaliplatin in combination with 5 Fluorouracil Pakistan Journal of Pharmaceutical Sciences 27(Special Issue 5): 1409-1418
Ueda, H.; Demizu, M.; Oosawa, M.; Chihara, S.; Nakanishi, Y.; Maeda, C.; Yano, K.; Kimura, F.; Iwakawa, S. 2009: Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(5): 789-793